Kohjin Bio
177A.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Revenue | ¥4.9bn | ¥5.2bn | ¥4.8bn | ¥4.7bn | ¥3.9bn |
| Operating income | ¥342m | ¥991m | ¥597m | ¥1.3bn | — |
| Ordinary income | ¥341m | ¥1.1bn | ¥636m | ¥1.2bn | ¥918m |
| Net income (owners) | ¥251m | ¥795m | ¥385m | ¥830m | ¥588m |
| Total assets | ¥8.9bn | ¥9.1bn | ¥6.6bn | ¥6.1bn | ¥5.6bn |
| Net assets / equity | ¥5.9bn | ¥5.8bn | ¥3.3bn | ¥3.0bn | ¥2.2bn |
| Operating cash flow | ¥699m | ¥916m | ¥824m | ¥461m | ¥763m |
| EPS (basic) | ¥49.11 | ¥157.57 | ¥92.43 | ¥199.23 | ¥173.5 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 5
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 201 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 187 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 45 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 173 figures · EDINET |
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Cell Process Business | ¥975m | ¥80m |
| Microbiological Business | ¥1.4bn | −¥95m |
| Tissue Culture Business | ¥2.5bn | ¥946m |
| Adjustments & eliminations | — | −¥590m |
| Total | ¥4.9bn | ¥932m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.